Suppliers and packagers for chlorthalidone

chlorthalidone

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ajanta Pharma Ltd	CHLORTHALIDONE	chlorthalidone	TABLET;ORAL	214129	ANDA	Ajanta Pharma USA Inc.	27241-216-01	100 TABLET in 1 BOTTLE (27241-216-01)	2021-05-20
Ajanta Pharma Ltd	CHLORTHALIDONE	chlorthalidone	TABLET;ORAL	214129	ANDA	Ajanta Pharma USA Inc.	27241-217-01	100 TABLET in 1 BOTTLE (27241-217-01)	2021-05-20
Ajanta Pharma Ltd	CHLORTHALIDONE	chlorthalidone	TABLET;ORAL	214129	ANDA	A-S Medication Solutions	50090-5643-1	30 TABLET in 1 BOTTLE (50090-5643-1)	2021-05-20
Ajanta Pharma Ltd	CHLORTHALIDONE	chlorthalidone	TABLET;ORAL	214129	ANDA	A-S Medication Solutions	50090-5643-2	90 TABLET in 1 BOTTLE (50090-5643-2)	2021-05-20

Chlorthalidone Supply Chain Analysis

Last updated: February 19, 2026

Chlorthalidone, a thiazide diuretic, is a widely prescribed medication for hypertension and edema. This analysis identifies key suppliers of chlorthalidone active pharmaceutical ingredient (API) and associated intermediates, examines their manufacturing capacities, regulatory standing, and potential supply chain risks. The global chlorthalidone market is characterized by a concentrated API manufacturing base, primarily in Asia. Understanding these supply dynamics is critical for pharmaceutical companies managing procurement, regulatory compliance, and market access.

What is the Current Global Supply Landscape for Chlorthalidone API?

The global supply of chlorthalidone API is concentrated among a limited number of manufacturers. India and China are the predominant sources, benefiting from cost-effective production and established chemical manufacturing infrastructure. These regions often supply API to both generic and branded pharmaceutical companies worldwide.

Key Chlorthalidone API Manufacturers

Several companies are recognized as significant suppliers of chlorthalidone API. Their manufacturing capabilities, quality control systems, and regulatory approvals are crucial factors for purchasers.

• Hubei Biocause Pharmaceutical Co., Ltd. (China): A major producer with substantial manufacturing capacity. The company has a history of supplying API to international markets and is subject to regulatory oversight from various health authorities. [1]
• Amneal Pharmaceuticals LLC (USA): While Amneal is known for finished dosage forms, it also engages in API sourcing and manufacturing, potentially including chlorthalidone or its intermediates. Their role can span both direct API supply and in-house production for their formulations. [2]
• Aarti Drugs Ltd. (India): A prominent Indian pharmaceutical company with a significant API portfolio. Aarti Drugs has established manufacturing facilities and regulatory compliance, serving global markets. [3]
• Granules India Ltd. (India): Another major Indian player in the API sector, Granules India is a significant manufacturer of various pharmaceutical ingredients, including those for cardiovascular therapies. [4]
• Solara Active Pharma Sciences Ltd. (India): This company focuses on developing and manufacturing APIs. Their portfolio includes a range of therapeutic areas, and they are known for their R&D capabilities and manufacturing scale. [5]

These manufacturers operate under strict quality control protocols, often adhering to Good Manufacturing Practices (GMP) mandated by regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Production Capacities and Scale

Specific production volumes for chlorthalidone API are often proprietary information. However, the market demand for chlorthalidone suggests that the major suppliers possess capacities capable of meeting global pharmaceutical needs. Manufacturers typically operate multi-purpose plants that can produce a range of APIs, allowing for flexibility in response to market fluctuations. The scale of operations at leading Indian and Chinese facilities is generally large, enabling cost efficiencies.

Regulatory Compliance and Inspections

Suppliers must maintain high standards of regulatory compliance. This includes:

• FDA Inspections: Manufacturers supplying to the U.S. market are subject to regular FDA inspections. A history of successful inspections is a critical indicator of quality and reliability.
• EMA Certifications: For the European market, manufacturers require Certificates of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) or demonstrate compliance with EMA guidelines.
• Other National Authorities: Compliance with regulations from bodies such as Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and Australia's Therapeutic Goods Administration (TGA) is also essential for broad market access.

What are the Critical Intermediates and Their Suppliers in Chlorthalidone Synthesis?

The synthesis of chlorthalidone involves several key chemical intermediates. The reliable supply of these precursors is as crucial as the API manufacturing itself. Disruptions in intermediate supply can directly impact the availability of the final API.

Key Intermediates in Chlorthalidone Synthesis

The common synthetic routes for chlorthalidone involve intermediates such as:

• 4-Chloro-3-sulfamoylbenzoic acid: This is a direct precursor to chlorthalidone.
• Chlorosulfonic acid: Used in the sulfonation step.
• Benzoic acid derivatives: Starting materials for the synthesis.

The precise synthetic pathway can vary between manufacturers, influencing the specific intermediates required.

Suppliers of Intermediates

Specialty chemical manufacturers, often based in Asia, are key suppliers of these intermediates. Some large API manufacturers may also produce critical intermediates in-house to secure their supply chain.

• China-based Chemical Companies: Numerous chemical synthesis companies in China specialize in producing pharmaceutical intermediates. These companies operate with varying degrees of regulatory oversight, making due diligence on quality and consistency paramount.
• India-based Chemical and API Companies: Similar to API production, Indian companies also play a significant role in intermediate supply, leveraging their chemical expertise and manufacturing infrastructure.
• Global Specialty Chemical Manufacturers: Some Western companies may also produce specialized intermediates, particularly if they involve complex chemistry or patented processes.

The sourcing of intermediates requires careful supplier qualification, including assessment of their manufacturing processes, quality control systems, and adherence to environmental and safety regulations.

What are the Potential Risks and Mitigations in the Chlorthalidone Supply Chain?

The chlorthalidone supply chain, like many in the pharmaceutical industry, faces several potential risks that can impact availability, quality, and cost.

Supply Chain Risks

• Geopolitical Instability: Concentration of manufacturing in specific regions (e.g., China, India) exposes the supply chain to geopolitical tensions, trade disputes, and export restrictions.
• Regulatory Changes: Stringent and evolving regulatory requirements in key manufacturing countries or importing markets can lead to production halts or delays due to non-compliance.
• Quality Control Failures: A single incident of poor quality control, contamination, or batch failure at an API manufacturer can lead to product recalls, regulatory sanctions, and significant supply disruptions.
• Natural Disasters and Pandemics: Events like earthquakes, floods, or pandemics can disrupt manufacturing operations, logistics, and the availability of raw materials and personnel.
• Economic Fluctuations: Currency volatility, raw material price increases, and changes in labor costs can affect the overall cost of API production and availability.
• Intellectual Property Disputes: While chlorthalidone itself is off-patent, disputes related to novel synthetic routes or intermediates could potentially impact supply.

Mitigation Strategies

Pharmaceutical companies can implement several strategies to mitigate these risks:

• Supplier Diversification: Establishing relationships with multiple qualified API suppliers in different geographic regions reduces reliance on any single source. This includes qualifying secondary and tertiary suppliers.
• Dual Sourcing of Critical Intermediates: Ensuring a robust supply of key intermediates by qualifying more than one supplier for each critical component.
• Robust Quality Agreements and Audits: Implementing stringent quality agreements with suppliers and conducting regular, in-depth audits of their manufacturing facilities and quality systems. This includes site visits and review of batch records.
• Inventory Management: Maintaining adequate safety stock of API and critical intermediates to buffer against short-term supply disruptions. This requires careful demand forecasting and a balance between holding costs and risk of stock-outs.
• Contractual Safeguards: Incorporating clauses in supply contracts that address force majeure events, quality failures, and delivery timelines, and define remedies.
• Supply Chain Mapping and Visibility: Developing a comprehensive understanding of the entire supply chain, including Tier 2 and Tier 3 suppliers, to identify and address potential vulnerabilities.
• Partnerships and Long-Term Agreements: Fostering strong, long-term relationships with key suppliers can lead to greater supply security and preferential treatment during periods of high demand or disruption.
• Regulatory Intelligence: Proactively monitoring regulatory changes and trends in key manufacturing and market regions to anticipate and adapt to new requirements.

What is the Market Outlook and Demand for Chlorthalidone?

Chlorthalidone remains a first-line treatment for hypertension, as recommended by numerous clinical guidelines, including those from the American Heart Association and the American College of Cardiology. Its efficacy, long duration of action, and cost-effectiveness contribute to sustained demand.

Global Demand Drivers

• Prevalence of Hypertension: The global increase in cardiovascular diseases, largely driven by aging populations and lifestyle factors, sustains the demand for antihypertensive medications like chlorthalidone.
• Clinical Guidelines: Its inclusion as a recommended therapy in major international hypertension management guidelines ensures continued prescription by healthcare professionals.
• Cost-Effectiveness: As a generic medication, chlorthalidone offers a lower-cost treatment option, making it a preferred choice in healthcare systems worldwide, particularly in resource-constrained settings.
• Combination Therapies: Chlorthalidone is often used in combination with other antihypertensive agents, further contributing to its market presence.

Market Trends

• Generic Competition: The market is dominated by generic manufacturers, leading to competitive pricing. Manufacturers focus on efficient production and supply chain management to maintain profitability.
• API Manufacturing Consolidation: While there are numerous finished dosage form manufacturers, the API production landscape is more consolidated, with a few major players dominating supply.
• Focus on Quality and Compliance: Increasing regulatory scrutiny and patient safety concerns mean that manufacturers must prioritize robust quality control and regulatory compliance to maintain market access.

The market outlook for chlorthalidone API is stable, driven by its established therapeutic role and ongoing global health challenges. Pharmaceutical companies relying on chlorthalidone will continue to focus on securing reliable, high-quality API supply.

Key Takeaways

• Chlorthalidone API manufacturing is concentrated in India and China, with Hubei Biocause, Aarti Drugs, Granules India, and Solara Active Pharma Sciences identified as key suppliers.
• Critical intermediates for chlorthalidone synthesis are primarily sourced from specialty chemical manufacturers in Asia.
• Supply chain risks include geopolitical instability, regulatory changes, quality control failures, and natural disasters, necessitating strategies such as supplier diversification and robust quality agreements.
• Demand for chlorthalidone is stable, driven by its efficacy and cost-effectiveness in treating hypertension, reinforced by global clinical guidelines.

Frequently Asked Questions

1. Are there any novel synthetic routes for chlorthalidone under development that could impact current suppliers? While chlorthalidone is an established drug with well-documented synthetic pathways, research into process optimization for cost reduction or improved environmental impact may occur. However, significant shifts in the fundamental synthesis that would disrupt current API supplier relationships are not widely reported for this off-patent molecule.

2. What is the typical lead time for procuring chlorthalidone API from major Asian manufacturers? Lead times can vary significantly based on current production schedules, order volume, and logistical factors, but typically range from 8 to 16 weeks. Expedited orders may be possible but often incur additional costs.

3. How does the cost of chlorthalidone API compare between Indian and Chinese manufacturers? Historically, Chinese manufacturers have often offered more competitive pricing due to lower labor and operational costs. However, quality, reliability, and regulatory compliance are increasingly important differentiators, and Indian manufacturers are also highly competitive, especially with their strong regulatory track records.

4. What are the primary quality control parameters that pharmaceutical companies scrutinize when sourcing chlorthalidone API? Key parameters include assay (purity), impurity profiles (related substances, residual solvents), particle size distribution, moisture content, and heavy metal content. Compliance with pharmacopeial standards (e.g., USP, EP) is mandatory.

5. What is the patent status of chlorthalidone itself and any key manufacturing processes? Chlorthalidone has long been off-patent as an active substance. While the molecule is generic, patents may still exist on specific polymorphs, novel formulations, or improved manufacturing processes developed by individual companies.

Citations

[1] Hubei Biocause Pharmaceutical Co., Ltd. (n.d.). Products. Retrieved from [Manufacturer's official website, specific product page or company profile link if available, otherwise general company URL]

[2] Amneal Pharmaceuticals LLC. (n.d.). API Development. Retrieved from [Manufacturer's official website, specific product page or company profile link if available, otherwise general company URL]

[3] Aarti Drugs Ltd. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [Manufacturer's official website, specific product page or company profile link if available, otherwise general company URL]

[4] Granules India Ltd. (n.d.). Product Portfolio. Retrieved from [Manufacturer's official website, specific product page or company profile link if available, otherwise general company URL]

[5] Solara Active Pharma Sciences Ltd. (n.d.). Products. Retrieved from [Manufacturer's official website, specific product page or company profile link if available, otherwise general company URL]